Milestone Pharmaceuticals Inc Corporate Update Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Ritu Baral - Cowen and Company LLC - Analyst : Good morning, guys. Thanks for taking the question. Just a couple on my front on -- more on the payer side. One, very briefly, if you could give us the Medicare commercial split as you see it right now. But the bigger questions are two. In your payer conversations, what are your current expectations for prior off before coverage? Is there any requirement for like documentation of events, documentation of a certain number of events that translate to severity? And then I have a quick follow-up.

Question: Ritu Baral - Cowen and Company LLC - Analyst : Very helpful. And a quick follow-up, what do you guys expect for time lines to formulary inclusion and sort of more standard coverage and uptake? Thanks.

Question: Ritu Baral - Cowen and Company LLC - Analyst : Great. Thanks so much.

Question: Edward Tenthoff - Piper Jaffray Inc - Analyst : Great, thank you guys. Sincere congratulations on a long windy road, but your persistence for these patients is notable and finally rewarded. So sincere congratulations. I wanted to get a little bit clearer -- a little clarity on two issues. One, I know you said that it would be available in retail pharmacies in the first quarter. Can you give us any more sense what that means? Is that early in the new year? Does it kind of depend regionally where you roll out? What outreach to physicians goes in hand with that in terms of making them aware of availability. And then secondly, on price, I appreciate the color both with the WACC and the price per patient, which has been very consistent. What are the factors that kind of go into that. I think the biggest being, if they use one or two doses per episode, but how should we be thinking about that price revenue to you guys in a little bit more detail? Thank you.